Stem cell and induced pluripotent stem cell companies develop cells, therapies and research platforms capable of modelling development, disease and tissue regeneration. Their technologies support drug discovery, regenerative medicine, toxicology and advanced therapeutic development.
This category includes companies working on:
Browse 46 UK stem cell and iPSC companies below.
AI-native platform for cell culture process design and optimisation
Tolemy Bio Ltd is a company developing an AI-native platform for cell therapy process development and manufacturing optimisation. The platform ingests experimental and bioreactor data including cell growth, phenotype, potency, and metabolite profiles, then applies causal AI models to identify the biological drivers of…
Allogeneic neutrophil cell therapy platform for solid tumours
LIfT BioSciences is a biotechnology company developing a first-in-class allogeneic neutrophil immunotherapy for the treatment of solid tumours. Its platform produces Immuno-Modulatory Alpha Neutrophils (IMANs) from donor haematopoietic or induced pluripotent stem cells using a proprietary enhancement process. IMANs…
Engineered iPSC-derived exosomes for tissue-targeted drug delivery
Excellio Labs is a biotech developing engineered exosome platforms for targeted drug delivery. The technology exploits the inherent tissue-specificity of iPSC-derived extracellular vesicles, which are further surface-modified to create precision drug carriers capable of delivering nucleic acids, proteins, and small…
Cell culture media, reagents, and instruments for life sciences
STEMCELL Technologies UK is the British subsidiary of STEMCELL Technologies Canada Inc., a privately held Canadian biotechnology company founded in 1993. The Cambridge facility serves as the company's European hub for sales, marketing, research and development, and customer training, supporting researchers across the…
AI live cell imaging platform for stem cell therapy development
CellVoyant is a biotech developing AI-powered live cell imaging and process optimisation platforms for stem cell therapy development. The technology uses computer vision and neural network models to predict stem cell differentiation behaviour in real time, without destructive sampling, enabling earlier and more…
Stem cell platform for precision psychiatry and drug discovery
MeOmics Precision Medicine is a biotechnology company developing a precision psychiatry platform that combines genomics, phenomics, and stem cell-based cellular assays to generate biomarkers for severe mental illness. Patient-derived neurons, stimulated via multi-electrode array recording, produce electrophysiological…
AI bioprocess operating system for cell and gene therapy manufacturing
Native Labs Ltd is a software company developing an AI-powered bioprocess operating system for cell and gene therapy manufacturing. The platform unifies heterogeneous manufacturing data, including bioreactor time series, multi-omics, and batch records, into standardised AI-ready datasets. Neural network models enable…
Stem cell-derived exosome platform for targeted drug delivery
ReNeuron is a biotechnology company developing a stem cell-derived exosome platform for targeted therapeutic delivery. Founded on over two decades of stem cell science, including the world's first clinical trial of conditionally immortalised neural stem cell therapy for stroke disability, the company has pivoted to…
Programmable RNA for scalable cell engineering and biomanufacturing
Plurify is a biotechnology company developing PluRNA, a programmable RNA platform for sustained protein expression without genome integration. Its technology is designed to engineer cells through controllable RNA-based programmes, with applications in stem-cell therapy manufacturing, cell purification, biologics…
Gene therapy biotech targeting neural circuit dysfunction
Sania Therapeutics is a biotechnology company developing genetic medicines for diseases caused by dysfunctional neural circuits. Its approach combines precision AAV delivery to selected neural circuits with tuneable neuromodulation, using human iPSC-derived neural models to direct the evolution of human-centric…
Reprogrammed stem cell therapies for vascular disease and chronic wounds
ReproGo is a Belfast-based regenerative medicine company developing Advanced Therapy Medicinal Products through direct cell reprogramming of adult cells into vascular lineages. The company's manufacturing approach produces stem cell-derived vascular cells and organoids through a xeno-free, low-dose process designed…
Approved presbyopia eye drops and investigational retinal therapies
Tenpoint Therapeutics is an ophthalmic biopharmaceutical company developing medicines and regenerative cell therapies for age-related vision disorders. Its dual-agent carbachol/brimonidine eye drops received US FDA approval for presbyopia in January 2026 and became commercially available in March. A UK regulatory…
Automated cell culture platform and stem cell lines for biomanufacturing
Unicorn Biotechnologies is a Sheffield-based company developing automated cell culture instruments and stem cell line products for research and biomanufacturing applications. Its platform is a modular, closed-loop cell culture robot that standardises and scales cell culture workflows across drug discovery,…
Synthetic platform for precision delivery of biologics in tissue repair
Renovos Biologics is a biotech company developing precision delivery technologies for regenerative medicine, drawing on decades of academic research in skeletal stem cells, biomaterials and translational orthopaedic science at the University of Southampton. Its proprietary synthetic platform enables injectable,…
Private umbilical cord blood and tissue stem cell banking service
Future Health Biobank is the UK's largest private stem cell bank, providing collection, processing, and long-term cryogenic storage of umbilical cord blood and cord tissue for families. Operating from an HTA- and MHRA-licensed laboratory in Nottingham, the company performs in-house PCR, serology, and flow cytometry…
Human cardiomyocyte assays for cardiac safety pharmacology
Clyde Biosciences is a contract research organisation specialising in human cardiomyocyte assays for cardiac drug safety and efficacy. Its optical platform measures membrane voltage, calcium dynamics and contraction in induced pluripotent stem cell-derived cardiomyocytes within a single experiment, generating…
Biomimetic cell culture platform for reproducible cell therapy development
Stembond Technologies is a Cambridge University spin-out developing a synthetic, mechanically tuned biomimetic substrate that replicates the physical properties of human tissue microenvironments. The platform delivers reproducible cell culture conditions, reducing phenotypic drift and improving consistency across…
Stem cell therapies for equine musculoskeletal injuries
BioDivide Limited is a regenerative medicine company developing and commercialising stem cell therapies, with a current focus on equine musculoskeletal conditions. Its product uses a non-invasive proprietary method to collect and process stem cells from horses, delivering a standardised, frozen, ready-to-inject…
University spatial transcriptomics and imaging platform for tissue research
The DRP Spatial Platform is a university core facility that supports spatial transcriptomics and imaging projects. It offers experimental design, histology and sample preparation, tissue imaging and laser capture microdissection, and spatial gene expression profiling, with support for data quality control and…
Quality-controlled human iPSC lines for disease modelling
EBiSC is a not-for-profit biobank supplying quality-controlled human induced pluripotent stem cell (iPSC) lines to academic and commercial researchers. Its catalogue includes disease-associated, healthy control and gene-edited isogenic cell lines for disease modelling, drug discovery and preclinical research. The…